Frågedatum: 2002-08-30
RELIS database 2002; id.nr. 19110, DRUGLINE
www.svelic.se

Utredningen som riktar sig till hälso- och sjukvårdspersonal, har utformats utefter tillgänglig litteratur och resurser vid tidpunkten för utredning. Innehållet i utredningen uppdateras inte. Hälso- och sjukvårdspersonal är ansvarig för hur de använder informationen vid rådgivning eller behandling av patienter.


Could mianserin interact with alcoholic beverages? Is there a risk of developing an addiction to th



Fråga: Could mianserin interact with alcoholic beverages? Is there a risk of developing an addiction to the substance? Could mianserin be abused?

A patient with alcohol dependence, takes 60-90 mg mianserin a day to feel calmer but also to achieve inebriation.

Sammanfattning: There is no known pharmacokinetic interaction between alcohol and mianserin. There are some evidence for pharmacodynamic interaction, at least additive effect, on sedation and impairment in coordination and balance test particularly during the first days of combination. There is a risk of unpleasant symptoms during withdrawal that could explain a potential for continuing the medication longer than needed to treat the depression. We have not found any reports of enhanced effect of alcohol inebriation after concurrent use of mianserin.

Svar: Mianserin is a tetracyclic antidepressant that is an antagonist at 5HT1 and 5HT2 receptors (1). It also antagonize alpha2- and alpha1-adrenoreceptors and thus increases norepinephrine release (1). There is no known pharmacokinetic interaction between alcohol and mianserin (2-3). Mianserin is a sedative drug, mainly through 5HT-receptor antagonism, and it is thus assumed that it enhances depressant actions of other sedative drugs, particularly alcohol (1). However, in one study of healthy volunteers, the sedative effect of mianserin was not enhanced by combination of alcohol, although the combination had at least an additive effect on the impaired of performance seen in a variety of tests measuring balance, concentration, and motor ability (2). In another similar study, the additive sedation was confirmed between mianserin and alcohol (4). Coordination was impaired only during the first day of combined intake (4).

The potential risk developing addiction to mianserin is hard to assess. For many antidepressants there are reports of withdrawal problems (5-11). The wish to avoid the symptoms of withdrawal could be one reason to continue the medication.

We are not aware of the use of mianserin to enhance alcohol-induced inebriation. Theoretically, antagonism at 5HT1- and 5HT2-receptors, could increase the level of 5HT present to bind to 5HT3 receptors. There is some evidence in humans that some of the pleasurable effects of alcohol are mediated by binding to 5HT3 receptors (12). This is highly speculative though. 1 Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999. 2 Stromberg C, Mattila MJ. Acute comparison of clovoxamine and mianserin, alone and in combination with ethanol, on human psychomotor performance. Pharmacol Toxicol 1987;60:374-9. 3 Liljequist R, Seppala T, Mattila MJ. Amitriptyline- and mianserin-induced changes in acquisition of paired-association learning-task. Br J Clin Pharmacol 1978;5:149-53. 4 Seppala T, Stromberg C, Bergman I. Effects of zimeldine, mianserin and amitriptyline on psychomotor skills and their interaction with ethanol a placebo controlled cross-over study. Eur J Clin Pharmacol 1984;27:181-9.

5 Klesmer J, Sarcevic A, Fomari V. Panic attacks during discontinuation of mirtazepine. Can J Psychiatry 2000;45:570-1.
6 Benazzi F. Mirtazapine withdrawal symptoms. Can J Psychiatry 1998;43:525.
7 Johnson H, Bouman WP, Lawton J. Withdrawal reaction associated with venlafaxine. 1998. BMJ 317:787.

8 Haddad PM, Devarajan S, Dursun SM. Antidepressant discontinuation (withdrawal) symptoms presenting as "stroke". J Psychopharmacol 2001;15:139-41. 9 Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998;12(3):305-13. 10 Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000 May;25(3):255-61. 11 Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997;58 Suppl 7:11-5 (discussion 16). 12 Radel M, Goldman D. Pharmacogenetics of alcohol response and alcoholism: the interplay of genes and environmental factors in thresholds for alcoholism. Drug Metab Dispos 2001;29:489-94.

Referenser: